Skip to content
    Back to Archive

    2026 Archive

    215 articles from 2026

    Multimodal Immunotherapy and Chemoradiotherapy Strategies in Locally Advanced Lung Cancer

    Author: Xu et al
    Journal: Journal of translational internal medicine
    Published 17 days ago

    TITLE: Multimodal Immunotherapy and Chemoradiotherapy Strategies in Locally Advanced Lung Cancer SUMMARY: Platinum-based concurrent chemoradiotherapy (cCRT) followed by consolidation immune-checkpoin...

    The 2026 World Health Organization Classification of Tumors of Soft Tissue and Bone: 6th Edition

    Author: Hornick et al
    Journal: The American Journal of Surgical Pathology
    Published about 1 month ago

    TITLE: 2026 WHO Classification of Soft Tissue and Bone Tumors (6th Edition): Key Diagnostic Updates and New Entities SUMMARY: The 6th edition of the World Health Organization (WHO) Classification of ...

    TITLE: Five-Year Survival Outcomes in Non-pCR Esophageal Squamous Cell Carcinoma: Neoadjuvant Immunochemotherapy vs Chemotherapy Alone SUMMARY: In a propensity score-matched real-world cohort study o...

    TITLE: Oncology Nurse Perspectives on Home Parenteral Cancer Therapy: Safety Concerns and Implementation Needs SUMMARY: A descriptive qualitative study evaluated the perspectives of hospital oncology...

    Obesity in survivors of childhood cancer

    Author: Helin et al
    Journal: Annals of Pediatric Endocrinology & Metabolism
    Published about 2 months ago

    TITLE: Overweight and Obesity Trajectories in Childhood Cancer Survivors: Risk Factors and Clinical Timeline SUMMARY: A historical cohort study evaluating 820 pediatric cancer survivors treated at a ...

    Physical Activity and Risk of Liver Cancer: A Competing Risk Analysis

    Author: Albers et al
    Journal: International Journal of Cancer
    Published about 2 months ago

    TITLE: Physical Activity Reduces Liver Cancer Incidence in Competing Risk Analysis: NIH-AARP Study SUMMARY: In a causal competing risk analysis of 263,184 participants from the NIH-AARP Diet and Heal...

    TITLE: Mortality Trends for Concurrent Alzheimer's Disease and Cancer in Older US Adults: 1999–2023 CDC WONDER Analysis SUMMARY: A population-based descriptive time-trend analysis using CDC WONDER mu...

    Every VoiceCAN: the journey and contributions of a grassroots regional cancer advisory network

    Author: Wilkins et al
    Journal: Research Involvement and Engagement
    Published about 2 months ago

    TITLE: Regional Cancer Advisory Model Expands Rural Patient Engagement Across Clinical Networks SUMMARY: Participation rates in cancer clinical trials remain persistently low across rural, regional, ...

    TITLE: Liso-cel vs Axi-cel in Diffuse Large B-Cell Lymphoma: FAERS Real-World Analysis Identifies Lower Odds of CRS, ICANS, and Cytopenias SUMMARY: A real-world pharmacovigilance study evaluating dat...

    Feasibility of a prospective real-time monitoring system capturing real-world data from elderly patients with acute myeloid leukemia

    Author: Hermans et al
    Journal: ESMO Real-World Data and Digital Oncology
    Published about 2 months ago

    TITLE: Automated Prospective Real-World Data Capture Validated Against Clinical Trial Controls in Older AML Patients SUMMARY: An automated, prospective real-time monitoring system successfully extrac...

    ESTRO consensus recommendations on total skin electron beam technique - Endorsed by ILROG

    Author: Moustakis et al
    Journal: Physics and Imaging in Radiation Oncology
    Published about 2 months ago

    TITLE: ESTRO and ILROG Consensus Recommendations for Total Skin Electron Beam Therapy in Cutaneous T-Cell Lymphoma SUMMARY: Total skin electron beam therapy (TSEBT) is an established radiation therap...

    TITLE: Real-World Adoption of PD-(L)1 Inhibitors in Medicare-Eligible Triple-Negative Breast Cancer SUMMARY: In a retrospective analysis assessing real-world oncology practice patterns, immune checkp...

    Understanding return to work after breast cancer through real-world data linkage framework: a Luxembourg digital oncology use case

    Author: Lima et al
    Journal: ESMO Real-World Data and Digital Oncology
    Published about 2 months ago

    TITLE: Real-World Data Linkage Demonstrates 77% Return-to-Work Rate Following Breast Cancer SUMMARY: Evaluating return to work (RTW) among working-age women diagnosed with breast cancer requires the ...

    Tozuleristide Fluorescence-Guided Resection of Gliomas: Results of a Phase II Investigator-Initiated Study

    Author: Fox et al
    Journal: Operative Neurosurgery
    Published about 2 months ago

    TITLE: Tozuleristide Near-Infrared Fluorescence in Glioma Resection: Phase II Diagnostic and Resection Outcomes SUMMARY: In a Phase II, investigator-initiated, nonrandomized clinical trial, researche...

    TITLE: CDC Initiative Develops Computable EHR Decision Support Tools for Cervical, Breast, and Colorectal Cancer Screening SUMMARY: Translating narrative clinical practice guidelines into routine cli...

    TITLE: EVITA Trial: Oral Vitamin C in Clonal Cytopenia of Undetermined Significance and Lower-Risk Myeloid Malignancies SUMMARY: The phase 2 EVITA trial evaluated the clinical impact, biological acti...

    TITLE: Pulmonary Nodule Risk Stratification and Lung Cancer Screening Gaps in Never-Smokers: Real-World Evidence Review SUMMARY: Current lung cancer screening guidelines and pulmonary nodule risk ass...

    Few cancer survivors returned to oncology after primary care transition, cohort finds

    Author: Fishbein et al
    Journal: J Cancer Surviv
    Published 3 months ago

    TITLE: Primary Care Transition Safety in Cancer Survivors: Recurrence Rates and Re-Access Outcomes in a Retrospective Cohort Study SUMMARY: In a retrospective cohort study conducted at the Juravinski...

    TITLE: Phase 3 TALENTOP Trial: Liver Resection Post-Atezolizumab/Bevacizumab Prolongs Time to Treatment Failure in Advanced Hepatocellular Carcinoma SUMMARY: The multicentre, open-label, randomised p...

    Fractional CO2 Vaginal Laser Therapy for GSM in Breast Cancer Survivors

    Author: Jacobsen et al
    Journal: Lasers Surg Med
    Published 3 months ago

    TITLE: Session-Dependent Efficacy of Fractional CO2 Vaginal Laser Therapy for Genitourinary Syndrome of Menopause in Breast Cancer Survivors SUMMARY: Genitourinary syndrome of menopause (GSM) is a pr...

    Population genomic screening cohort shows high satisfaction and follow-up care

    Author: English et al
    Journal: J Genet Couns
    Published 3 months ago

    TITLE: Population Genomic Screening for HBOC and Lynch Syndrome: Clinical Follow-Up and Longitudinal Patient Outcomes SUMMARY: An evaluation of the 'In Our DNA SC' population-wide genomic screening (...

    STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial

    Author: Herper and Chen
    Journal: STAT
    Published 3 months ago

    TITLE: Personalized mRNA Vaccine Intismeran Plus Pembrolizumab Slows Recurrence in Phase 3 Melanoma Trial SUMMARY: In a randomized Phase 3 clinical trial, adding the personalized mRNA neoantigen vacc...

    Cost-Effectiveness of First-Line Immunotherapy Regimens in Advanced PD-L1-Positive TNBC

    Author: Sun et al
    Journal: J Evid Based Med
    Published 3 months ago

    TITLE: Cost-Effectiveness of First-Line Immunotherapy Regimens in Advanced PD-L1-Positive Triple-Negative Breast Cancer SUMMARY: An exploratory cross-trial partitioned survival model evaluated the co...

    Japanese Guidelines Support Geriatric Assessment to Mitigate Toxicity in Older Cancer Patients

    Author: Ohmura et al
    Journal: Int J Clin Oncol
    Published 3 months ago

    TITLE: Japanese Guidelines Support Geriatric Assessment to Mitigate Pharmacotherapy Toxicity in Older Cancer Patients SUMMARY: The Japanese Society of Medical Oncology and the Japanese Society of Cli...

    Targeted total neoadjuvant therapy trial yields 40% complete response in rectal cancer

    Author: Ma et al
    Journal: Signal Transduction and Targeted Therapy
    Published 3 months ago

    TITLE: Biomarker-Driven Total Neoadjuvant Therapy in High-Risk Rectal Cancer: Phase 2 TRAINER Study SUMMARY: The single-center, multicohort phase 2 TRAINER trial evaluated a personalized, biomarker-d...

    Belinostat shows 30.5% response rate in relapsed refractory T-cell lymphoma cohort

    Author: Menguc et al
    Journal: Journal of Clinical Medicine
    Published 3 months ago

    TITLE: Real-World Outcomes of Belinostat in Relapsed or Refractory T-Cell Lymphomas: A Turkish Multicenter Study SUMMARY: In a retrospective multicenter study conducted by the Lymphoma Study Group of...

    CDCP1-targeted antibody-drug conjugates and immunocytokines for cancer therapy

    Author: Mu et al
    Journal: Cancer Chemotherapy and Pharmacology
    Published 3 months ago

    TITLE: Preclinical Efficacy of CDCP1-Targeted ADCs and Immunocytokines in Solid Tumors SUMMARY: CUB domain-containing protein 1 (CDCP1) is a tumor-associated surface antigen broadly expressed across ...

    RADICAL Trial Evaluates Radium-223 Dichloride Plus Cabozantinib in Renal Cell Carcinoma

    Author: McKay et al
    Journal: Journal of Clinical Oncology
    Published 3 months ago

    TITLE: RADICAL Trial Evaluates Radium-223 Dichloride Plus Cabozantinib in Renal Cell Carcinoma With Bone Metastases SUMMARY: The phase II randomized RADICAL trial (Alliance A031801), published ahead ...

    G-oncoCOACH: Geriatric Assessment and Patient Coaching in Older Adults With Solid Tumors

    Author: Ravoet et al
    Journal: Journal of Geriatric Oncology
    Published 3 months ago

    TITLE: G-oncoCOACH: Comprehensive Geriatric Assessment and Patient Coaching in Older Adults With Solid Tumors SUMMARY: The G-oncoCOACH study evaluates secondary endpoints, including treatment-related...

    Izalontamab Brengitecan Evaluated in Extensive-Stage Small Cell Lung Cancer Phase Ib Trial

    Author: Zhao et al
    Journal: Journal of Clinical Oncology
    Published 3 months ago

    TITLE: Izalontamab Brengitecan Evaluated in Extensive-Stage Small Cell Lung Cancer Phase Ib Trial SUMMARY: Izalontamab brengitecan (Iza-Bren) is a first-in-class bispecific antibody-drug conjugate (A...

    Exercise Interventions and Quality of Life in Older Adults With Cancer

    Author: Wang et al
    Journal: Journal of Geriatric Oncology
    Published 3 months ago

    TITLE: Exercise Interventions and Quality of Life in Older Adults With Cancer: A Systematic Review and Meta-Analysis SUMMARY: A systematic review and meta-analysis published in the Journal of Geriatr...

    Management of older adults with colorectal cancer – The state-of-the-art in 2026

    Author: Liposits et al
    Journal: Journal of Geriatric Oncology
    Published 3 months ago

    TITLE: Management of Older Adults With Colorectal Cancer: 2026 State-of-the-Art Review SUMMARY: A state-of-the-art review on the management of older adults with colorectal cancer was published in the...

    Integrating General Practice into Oncological Decision-Making for Frail Patients

    Author: Stegmann et al
    Journal: Journal of Geriatric Oncology
    Published 3 months ago

    TITLE: Integrating General Practice into Oncological Decision-Making for Frail Patients SUMMARY: A framework published in the Journal of Geriatric Oncology outlines a strategy for integrating general...

    Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0

    Author: Lesnock et al
    Journal: Journal of Clinical Oncology
    Published 3 months ago

    TITLE: ASCO Updates Living Guideline Version 2026.1.0 on Systemic Treatment for Recurrent Ovarian Cancer SUMMARY: The American Society of Clinical Oncology (ASCO) has published Version 2026.1.0 of it...

    Consensus research priorities in geriatric oncology: A Delphi study

    Author: Drury et al
    Journal: Journal of Geriatric Oncology
    Published 3 months ago

    TITLE: Consensus Research Priorities in Geriatric Oncology: Insights From a Delphi Study SUMMARY: A Delphi expert consensus study published in the Journal of Geriatric Oncology identified core resear...

    Predicting Perioperative FLOT Outcomes in Resectable Gastric and GEJ Adenocarcinoma

    Author: Agnes et al
    Journal: European Journal of Surgical Oncology
    Published 3 months ago

    TITLE: Predicting Perioperative FLOT Outcomes in Resectable Gastric and GEJ Adenocarcinoma via Pathologic and Molecular Features SUMMARY: A real-world retrospective cohort study published in the Euro...

    COG AAML1831 Phase III Trial: CPX-351 vs Standard Induction Therapy in De Novo Pediatric AML

    Author: Pollard et al
    Journal: Journal of Clinical Oncology
    Published 3 months ago

    TITLE: COG AAML1831 Phase III Trial: CPX-351 vs Standard Induction Therapy in De Novo Pediatric AML SUMMARY: The Children's Oncology Group reported findings from AAML1831, a Phase III clinical trial ...

    Prior-guided multi-expert consensus fusion for multi-center thyroid nodule classification

    Author: Li et al
    Journal: Artificial Intelligence in Medicine
    Published 3 months ago

    TITLE: AI-Driven Multi-Center Thyroid Nodule Classification via Multi-Expert Consensus Fusion SUMMARY: This study, published in Artificial Intelligence in Medicine, introduces a prior-guided multi-ex...

    DPYD-Guided Metronomic Capecitabine and Vinorelbine in Metastatic HER2-Negative Breast Cancer

    Author: Schettini et al
    Journal: JCO Precision Oncology
    Published 3 months ago

    TITLE: DPYD-Guided Metronomic Capecitabine and Vinorelbine in Metastatic HER2-Negative Breast Cancer: Real-World Analysis SUMMARY: This real-world retrospective study, published in JCO Precision Onco...

    Long-Term Overall Survival in BRAF V600–Mutant Advanced Melanoma: COMBI-I

    Author: Ribas et al
    Journal: Journal of Clinical Oncology
    Published 3 months ago

    TITLE: Long-Term Overall Survival with Spartalizumab, Dabrafenib, and Trametinib in BRAF V600–Mutant Advanced Melanoma: COMBI-I Findings SUMMARY: The COMBI-I study, published in the Journal of Clinic...

    Phase III trial updates efficacy and safety of neoadjuvant Daromun in melanoma

    Author: Hauschild et al
    Journal: Journal of Clinical Oncology
    Published 3 months ago

    TITLE: Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: PIVOTAL Phase III Trial Update SUMMARY: The PIVOTAL Phase III trial investigated the efficacy and saf...

    Adjusting PSA density thresholds optimizes prostate cancer diagnosis, study finds

    Author: Prinsen et al
    Journal: European Urology Oncology
    Published 3 months ago

    TITLE: MR-PROPER Study: Optimizing PSA Density Thresholds for MRI-Directed Prostate Cancer Diagnosis SUMMARY: The community-based, multicentre MR-PROPER study, published in European Urology Oncology,...

    HRD Testing and MYC Amplification in BRCA-Wild-Type High-Grade Serous Carcinoma

    Author: Maradiya et al
    Journal: Gynecologic Oncology
    Published 3 months ago

    TITLE: HRD Testing Utility and MYC Amplification as a Surrogate Marker in BRCA-Wild-Type High-Grade Serous Carcinoma SUMMARY: This research evaluates the real-world application of homologous repair d...

    Drug exposure definitions reported in real-world evidence studies on oncology medicines in patients with colorectal cancer: a scoping review

    Author: van Dommelen et al
    Journal: ESMO Real World Data and Digital Oncology
    Published 3 months ago

    TITLE: Standardizing Drug Exposure Definitions in Colorectal Cancer Real-World Evidence: A Scoping Review SUMMARY: Published in ESMO Real World Data and Digital Oncology, this scoping review evaluate...

    ASCO updates living guideline on stage IV NSCLC with driver alterations

    Author: Puri et al
    Journal: Journal of Clinical Oncology
    Published 3 months ago

    TITLE: ASCO Living Guideline Update 2026.3.2: Stage IV NSCLC With Driver Alterations SUMMARY: This update (Version 2026.3.2) from the American Society of Clinical Oncology (ASCO), published in the Jo...

    5-Year Results of First-Line Nivolumab Combinations in Advanced Esophageal Squamous Cell Carcinoma

    Author: Kato et al
    Journal: Annals of Oncology
    Published 3 months ago

    TITLE: 5-Year Results of First-Line Nivolumab Combinations in Advanced Esophageal Squamous Cell Carcinoma: CheckMate 648 SUMMARY: The CheckMate 648 trial evaluated the long-term clinical outcomes of ...

    Treatment of Multiple Myeloma: ASCO Living Guideline, Version 2026.1.1

    Author: Banerjee et al
    Journal: Journal of Clinical Oncology
    Published 3 months ago

    TITLE: ASCO Living Guideline Update for Multiple Myeloma Treatment: Version 2026.1.1 SUMMARY: The American Society of Clinical Oncology (ASCO) has released Version 2026.1.1 of its living guideline fo...

    SKYSCRAPER-01: First-Line Tiragolumab and Atezolizumab in PD-L1–High NSCLC

    Author: Peters et al
    Journal: Journal of Clinical Oncology
    Published 3 months ago

    TITLE: SKYSCRAPER-01: First-Line Tiragolumab and Atezolizumab in PD-L1–High NSCLC SUMMARY: The SKYSCRAPER-01 trial investigated the clinical application of dual checkpoint inhibition using tiragoluma...

    TITLE: ERBB2 Amplification in Endometrial Cancer: Impact on Molecular Subtypes and Real-World Outcomes SUMMARY: This research evaluates the clinical significance of ERBB2 (HER2) amplification in endo...

    Trial provides 5-year update on intismeran autogene plus pembrolizumab in melanoma

    Author: Adnan Khattak
    Journal: Journal of Clinical Oncology
    Published 4 months ago

    TITLE: Adjuvant Intismeran Autogene Plus Pembrolizumab in High-Risk Melanoma: 5-Year KEYNOTE-942 Update SUMMARY: The randomized Phase IIb KEYNOTE-942 study provides a 5-year update on the combination...

    Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update

    Author: Nahleh et al
    Journal: Journal of Clinical Oncology
    Published 4 months ago

    TITLE: ASCO Clinical Practice Guideline Update: Breast Cancer Follow-Up and Surveillance After Primary Treatment SUMMARY: The American Society of Clinical Oncology (ASCO) has released an updated clin...

    AI-HOPE: Multicenter Real-World Registry Integrating AI for Metastatic NSCLC

    Author: Ogliari et al
    Journal: ESMO Real World Data and Digital Oncology
    Published 4 months ago

    TITLE: AI-HOPE: Multicenter Real-World Registry Integrating AI for Metastatic NSCLC SUMMARY: The AI-HOPE (Artificial Intelligence-based Health Outcomes and Patient Experience) registry is a multicent...

    NMPA and Zhejiang Society Establish AI Dataset Standards for Cervical Cytology

    Author: Zhejiang Society
    Journal: Intelligent Oncology
    Published 4 months ago

    TITLE: NMPA and Zhejiang Society Establish AI Dataset Standards for Cervical Cytology SUMMARY: The Zhejiang Society for Mathematical Medicine, in collaboration with the National Medical Products Admi...

    WOMBAT Phase 2 Trial: Bipolar Androgen Therapy for nmCRPC Progressing on Darolutamide

    Author: Talmor et al
    Journal: European Urology Oncology
    Published 4 months ago

    TITLE: WOMBAT Phase 2 Trial: Bipolar Androgen Therapy for nmCRPC Progressing on Darolutamide SUMMARY: The WOMBAT (ANZUP 2201) trial is a phase 2, single-arm clinical study evaluating the use of Bipol...

    Feasibility and Impact of Pharmacist Medication Reviews in Geriatric Oncology Clinics

    Author: Mellor et al
    Journal: Journal of Geriatric Oncology
    Published 4 months ago

    TITLE: Feasibility and Impact of Pharmacist Medication Reviews in Geriatric Oncology Clinics SUMMARY: This study, published in the Journal of Geriatric Oncology, examines the role and feasibility of ...

    Real-World Registry Data for Adjuvant Pembrolizumab in High-Risk Renal Cell Carcinoma

    Author: Ouzaid et al
    Journal: European Urology Oncology
    Published 4 months ago

    TITLE: Real-World Registry Data for Adjuvant Pembrolizumab in High-Risk Renal Cell Carcinoma SUMMARY: This study, published in European Urology Oncology, evaluates real-world data regarding the use o...

    Real-World Adherence to EAU Guidelines for NMIBC Management and Impact on Oncological Outcomes

    Author: Longoni et al
    Journal: European Urology Oncology
    Published 4 months ago

    TITLE: Real-World Adherence to EAU Guidelines for NMIBC Management and Impact on Oncological Outcomes SUMMARY: This research, published in European Urology Oncology, examines the implementation of Eu...

    Irinotecan Added to Preoperative Chemoradiotherapy for High-Risk Rectal Cancer

    Author: Sebag-Montefiore et al
    Journal: The Lancet Oncology
    Published 4 months ago

    TITLE: Irinotecan Added to Preoperative Chemoradiotherapy for High-Risk Rectal Cancer: ARISTOTLE Trial Results SUMMARY: The phase 3 ARISTOTLE trial, a multicentre, open-label, randomised controlled s...

    SUPREMO Trial: 5-Year Quality-of-Life and Chest Wall Toxicity Following Postmastectomy Radiotherapy

    Author: Velikova et al
    Journal: The Lancet Oncology
    Published 4 months ago

    TITLE: SUPREMO Trial: 5-Year Quality-of-Life and Chest Wall Toxicity Following Postmastectomy Radiotherapy SUMMARY: The phase 3 randomized controlled SUPREMO trial evaluated the 5-year quality-of-lif...

    TITLE: Real-World Implementation of Early Palliative Care in Advanced Colorectal Cancer: The PALES Project SUMMARY: The Palliative Care Early and Systematic (PALES) project is a real-world study focu...

    TITLE: Safety and Management of Inavolisib Plus Palbociclib-Fulvestrant in PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer: INAVO120 Phase III Analysis SUMMARY: The Phase III INAVO120 trial evaluated...

    TITLE: Pirtobrutinib vs Standard Care for R/R CLL/SLL: Patient-Reported Outcomes From the BRUIN CLL-321 Trial SUMMARY: The Phase 3 BRUIN CLL-321 trial evaluated the clinical impact of pirtobrutinib, ...

    FDA Expands Pembrolizumab and Enfortumab Vedotin Approval for All Neoadjuvant MIBC Patients

    Author: Dorothy Brooks
    Journal: Medical Daily
    Published 4 months ago

    TITLE: FDA Expands Pembrolizumab and Enfortumab Vedotin Approval for All Neoadjuvant MIBC Patients SUMMARY: The FDA has expanded the approved indication for pembrolizumab (Keytruda) in combination wi...

    FDA approves Jideytro for previously treated ROS1-positive NSCLC

    Author: Matthew Shinkle
    Journal: Healio
    Published 4 months ago

    TITLE: FDA Approves Zidesamtinib (Jideytro) for Pretreated ROS1-Positive Advanced NSCLC SUMMARY: The FDA has approved zidesamtinib (Jideytro, GSK) for adults with locally advanced or metastatic ROS1-...

    TITLE: Management of Late Genitourinary Toxicity After Prostate Radiotherapy: Insights from the IRRADIaTE Registry SUMMARY: The IRRADIaTE (Italian Registry of Radiotherapy-Associated Disorders and Ur...

    TITLE: Phase III ENHANCE Trial: Magrolimab Plus Azacitidine Fails to Improve Outcomes in Higher-Risk MDS SUMMARY: The Phase III ENHANCE study, published in the Journal of Clinical Oncology, investiga...

    TITLE: Multidisciplinary Quality Improvement Reduces Time to Breast Cancer Surgery with Immediate Reconstruction SUMMARY: A retrospective cohort study involving 3,324 patients evaluated the impact of...

    FDA Greenlights Next-Generation ROS1 Inhibitor for Lung Cancer

    Author: Mike Bassett
    Journal: MedPage Today
    Published 4 months ago

    TITLE: FDA Approves Zidesamtinib for Pretreated Advanced ROS1-Positive NSCLC SUMMARY: The FDA has granted approval to zidesamtinib (Jideytro), a next-generation ROS1 inhibitor, for the treatment of a...

    TITLE: AdvanTIG-302: Ociperlimab Plus Tislelizumab Fails to Improve OS in PD-L1 High NSCLC SUMMARY: The Phase 3 AdvanTIG-302 trial investigated whether the addition of ociperlimab, an anti-TIGIT anti...

    Perioperative therapy in muscle-invasive bladder cancer: real-world evidence from the MINOTAURO study

    Author: Lainez et al
    Journal: ESMO Real World Data and Digital Oncology
    Published 4 months ago

    TITLE: Real-World Perioperative Management and Outcomes in Muscle-Invasive Urothelial Cancer: The MINOTAURO Study SUMMARY: The multicenter, retrospective MINOTAURO study analyzed real-world periopera...

    Next-Generation Sequencing Consensus Guidelines for Sarcoma: Progress, Gaps, and the Path Forward

    Author: V. Subbiah, MD & R. Kurzrock, MD
    Journal: Annals of Oncology
    Published 4 months ago

    TITLE: Consensus Guidelines for Next-Generation Sequencing (NGS) in Sarcoma Management SUMMARY: New consensus guidelines for the application of next-generation sequencing (NGS) in sarcoma have been p...

    TITLE: PERISCOPE II Trial: CRS plus HIPEC Fails to Improve Survival in Gastric Cancer with Limited Peritoneal Metastases SUMMARY: The multicentre, randomised, phase 3 PERISCOPE II trial evaluated the...

    Global Consensus on the Management of Primary Localized Chordoma

    Author: Radaelli et al
    Journal: JAMA Oncology
    Published 4 months ago

    TITLE: Global Consensus Update: Clinical Management of Primary Localized Chordoma in Pediatric and Adult Patients SUMMARY: This Special Communication provides a comprehensive update and expansion of ...

    TITLE: Cognitive Dysfunction Risk with Endocrine Therapy and CDK4/6 Inhibitors: FAERS Database Analysis SUMMARY: This real-world study, published in the Journal of Geriatric Oncology, utilized the FD...

    TITLE: Systematic Review of Liquid-Based Biomarkers for Upper Tract Urothelial Cancer Detection and Risk Stratification SUMMARY: This systematic review, conducted by the European Association of Urolo...

    TITLE: CGA-Guided Supportive Care Improves Longitudinal Quality of Life in Older Cancer Patients: The GOSPEL RCT SUMMARY: The GOSPEL randomized controlled trial investigated the impact of a specializ...

    TITLE: Enzalutamide plus Radium-223 Increases Overall Survival in First-Line mCRPC: Final PEACE-3 Trial Results SUMMARY: The final overall survival (OS) analysis of the phase III EORTC 1333/PEACE-3 t...

    TITLE: Management of De Novo Oligometastatic Breast Cancer: Real-World Physician Survey Results SUMMARY: This survey-based study analyzed the management preferences of 136 US medical oncologists rega...

    TITLE: Intensified Chemotherapy vs Standard Chemotherapy Plus Olaparib for Stage III HER2-Negative HRD Breast Cancer: The SUBITO Phase 3 Trial SUMMARY: The SUBITO phase 3 trial investigated whether i...

    TITLE: First-Line Ribociclib vs. Palbociclib in HR+/HER2− Metastatic Breast Cancer: Real-World Comparative Effectiveness Study SUMMARY: This global real-world evidence study evaluates the comparative...

    TITLE: Expert Consensus Guidelines for Reirradiation in Recurrent Head and Neck Squamous Cell Carcinoma SUMMARY: This policy review presents international expert consensus recommendations for managin...

    Refining Vascular Biomarker–Guided Risk Stratification for Cancer Therapy–Related Cardiac Dysfunction

    Author: Ze Xiang MD & Jian Wu PhD
    Journal: JACC: CardioOncology
    Published 5 months ago

    TITLE: Vascular Biomarker-Guided Risk Stratification for Cancer Therapy-Related Cardiac Dysfunction SUMMARY: Published in JACC: CardioOncology, this research by Ze Xiang and Jian Wu addresses the ref...

    TITLE: Amivantamab in Recurrent/Metastatic HNSCC Post-Immunotherapy: Phase 1b/2 OrigAMI-4 Trial Results SUMMARY: The phase 1b/2 OrigAMI-4 study (NCT06385080) evaluated the efficacy and safety of amiv...

    Large language models in oncology: promise, pitfalls, and the path to real-world adoption

    Author: McInerney et al
    Journal: ESMO Real World Data and Digital Oncology
    Published 5 months ago

    TITLE: Clinical Adoption and Implementation Frameworks for Large Language Models in Oncology SUMMARY: This review in ESMO Real World Data and Digital Oncology evaluates the clinical utility of large ...

    TITLE: Aumolertinib Plus Chemotherapy Improves PFS in EGFR-Mutated Advanced NSCLC: Phase 3 AENEAS2 Trial SUMMARY: The AENEAS2 trial, a multicenter, randomized, open-label, phase 3 study, evaluated th...

    Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†

    Author: de Azambuja et al
    Journal: Annals of Oncology
    Published 5 months ago

    TITLE: ESMO Clinical Practice Guidelines: Updated Recommendations for Metastatic Breast Cancer Management SUMMARY: The European Society for Medical Oncology (ESMO) has published updated Clinical Prac...

    Real-world treatment durability and pain management in older adults with metastatic castration-resistant prostate cancer

    Author: Cobran et al
    Journal: Journal of Geriatric Oncology
    Published 5 months ago

    TITLE: Real-World Treatment Durability and Pain Management in Older Adults with mCRPC SUMMARY: This research, published in the Journal of Geriatric Oncology, evaluates real-world treatment durability...

    TITLE: Trastuzumab and Survival Outcomes in HER2-Positive Biliary Tract Cancers: REAL TAB Real-World Analysis SUMMARY: The REAL TAB study is a real-world analysis published in JCO Oncology Advances t...

    Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.1

    Author: Reuss et al
    Journal: Journal of Clinical Oncology
    Published 5 months ago

    TITLE: ASCO Living Guideline Update: Therapy for Stage IV NSCLC With Driver Alterations SUMMARY: The American Society of Clinical Oncology (ASCO) has published an updated living guideline (version 20...

    TITLE: Home-Based Walking Program Mitigates Chemotherapy-Induced Cognitive Impairment: Phase 3 EXCAP Trial Results SUMMARY: The Phase 3 EXCAP trial demonstrates that a structured home-based walking e...

    TITLE: Predictive Value of Prior NMIBC History for Neoadjuvant Chemotherapy Response in Muscle-Invasive Bladder Cancer SUMMARY: This real-world analysis of the BLADRAC cohort investigates whether a p...

    TITLE: Mezigdomide-Carfilzomib-Dexamethasone Improves PFS in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: SUCCESSOR-2 Results SUMMARY: The Phase 3 SUCCESSOR-2 trial evaluated the effica...

    TITLE: Immunotherapy and Surgical Decision-Making in Lynch Syndrome-Associated Colorectal Cancer SUMMARY: This publication in the European Journal of Surgical Oncology examines the evolving intersect...

    Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: 2026 update

    Author: Nelson et al
    Journal: Gynecologic Oncology
    Published 5 months ago

    TITLE: 2026 ERAS Society Clinical Practice Guidelines for Gynecologic Oncology Update SUMMARY: The Enhanced Recovery After Surgery (ERAS®) Society has published its 2026 updated clinical practice gui...

    Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Clinical Insights

    Author: Park et al
    Journal: JCO Oncology Practice
    Published 5 months ago

    TITLE: ASCO Guideline Clinical Insights: Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer SUMMARY: This report, published in JCO Oncology Practice, provides clinical insights regarding the Ame...

    TITLE: ESMO Clinical Practice Guidelines: Management of Advanced and Metastatic Prostate Cancer SUMMARY: This ESMO Clinical Practice Guideline provides an updated, evidence-based framework for the ma...

    Endometrial cancer: A Society of Gynecologic Oncology evidence-based review and recommendations: Part I

    Author: Urban et al
    Journal: Gynecologic Oncology
    Published 6 months ago

    TITLE: SGO Evidence-Based Clinical Recommendations for Endometrial Cancer: Part I SUMMARY: This article represents Part I of the Society of Gynecologic Oncology (SGO) evidence-based review and clinic...

    TITLE: First-Line Afatinib vs. Osimertinib in NSCLC with Uncommon EGFR Mutations: Real-World Efficacy and Subtype Considerations SUMMARY: This multicenter retrospective cohort study conducted across ...

    TITLE: Real-World Comparison of Avelumab Maintenance vs. Second-Line Pembrolizumab in Metastatic Urothelial Cancer SUMMARY: This real-world study, conducted by the ProBCI Study Group and published in...

    TITLE: Real-World Management of Thrombocytopenia During First-Line Niraparib Maintenance in Epithelial Ovarian Cancer: The ACTIV1ZE Study SUMMARY: The ACTIV1ZE study investigates real-world clinical ...

    Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer

    Author: HERIZON-GEA-01 Investigators
    Journal: New England Journal of Medicine
    Published 6 months ago

    TITLE: Zanidatamab and Tislelizumab Improve Survival in HER2-Positive Advanced Gastroesophageal Cancer: Phase 3 Results SUMMARY: In the phase 3 HERIZON-GEA-01 trial, the dual HER2-targeted bispecific...

    TITLE: Lenvatinib Safety and Efficacy in Real-World Unresectable Hepatocellular Carcinoma: Final STELLAR Study Analysis SUMMARY: The Phase 4 STELLAR study, a prospective, non-interventional post-mark...

    TITLE: ESMO EnLiST Framework: Standardizing the Designation of Lines of Systemic Therapy in Solid Tumors SUMMARY: The European Society for Medical Oncology (ESMO) has developed the EnLiST (ESMO adapt...

    Chinese expert consensus on prostate cancer testosterone management (2025 edition)

    Author: China Anti-Cancer Association Male Reproductive System Tumors Committee
    Journal: Zhonghua Zhong Liu Za Zhi
    Published 6 months ago

    TITLE: 2025 Chinese Expert Consensus: Refined Testosterone Management in Prostate Cancer SUMMARY: The 2025 Chinese expert consensus on prostate cancer testosterone management addresses the increasing...

    International Consensus on Axillary Staging After Neoadjuvant Chemotherapy in Node-positive Breast Cancer

    Author: Lucocq et al
    Journal: European Journal of Surgical Oncology
    Published 6 months ago

    TITLE: International Consensus Guidelines for Axillary Staging After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer SUMMARY: This international consensus, published in the European Journal o...

    TITLE: Consensus Recommendations for ctDNA Use in HPV-Positive Oropharyngeal Carcinoma SUMMARY: The California Head and Neck Consortium has developed consensus recommendations for the clinical applic...

    AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway

    Author: Angus Liu
    Journal: Fierce Pharma
    Published 6 months ago

    TITLE: FDA Approves Datroway as First TROP2 ADC for First-Line Triple-Negative Breast Cancer SUMMARY: The FDA has granted approval to AstraZeneca and Daiichi Sankyo’s Datroway for the first-line trea...

    Publishing Prediction Models in Precision Oncology: A Summary of Guidelines and Recommendations

    Author: DelRocco et al
    Journal: JCO Precision Oncology
    Published 6 months ago

    TITLE: Guidelines and Recommendations for Publishing Prediction Models in Precision Oncology SUMMARY: This article, published in JCO Precision Oncology, offers a detailed summary of the guidelines an...

    TITLE: Fulvestrant vs. Capecitabine Maintenance for HR+/HER2- Metastatic Breast Cancer: Phase 3 FAMILY Trial Results SUMMARY: The multicenter, open-label, randomized phase 3 FAMILY trial compared the...

    TITLE: Sac-TMT and Pembrolizumab Combination Reduces Progression Risk by 65% in First-Line PD-L1-Positive NSCLC SUMMARY: An abstract released ahead of the ASCO 2026 annual meeting highlights signific...

    TITLE: HRR Gene Mutation Detection via Tumor Tissue and ctDNA Testing in Prostate Cancer: Phase III PROpel Trial Analysis SUMMARY: This analysis from the Phase III PROpel trial, published in JCO Prec...

    TITLE: International Guidelines for Breast Cancer Surveillance in CAYA Cancer Survivors Post-Anthracyclines SUMMARY: The International Guideline Harmonization Group (IGHG) has issued clinical recomme...

    Assessment of the Scandinavian guidelines on papillary thyroid cancer using the AGREE II instrument.

    Author: O’Neill et al
    Journal: European Journal of Surgical Oncology
    Published 6 months ago

    TITLE: AGREE II Assessment of Scandinavian Papillary Thyroid Cancer Clinical Guidelines SUMMARY: A research team led by Maria Sonesson O’Neill evaluated the quality of Scandinavian clinical practice ...

    Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

    Author: Angus Liu
    Journal: Fierce Pharma
    Published 6 months ago

    TITLE: FDA Expands Enhertu Indications to Early Breast Cancer Adjuvant Therapy SUMMARY: The FDA has issued dual approvals for Enhertu (trastuzumab deruxtecan) for the treatment of early breast cancer...

    TITLE: Concurrent vs Sequential Radiation Boost for High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial Results SUMMARY: The NRG/RTOG 1005 phase III trial evaluated the efficacy and safety o...

    TITLE: Dostarlimab and Multimodal Therapy for MMR-Deficient Uterine Large Cell Neuroendocrine Carcinoma SUMMARY: Large cell neuroendocrine carcinoma (LCNEC) of the uterus is a rare, aggressive malign...

    Efficacy of immunotherapy and targeted therapy for unresectable hepatocellular carcinoma: analysis of survival curves

    Author: Wan Zhou & Pan Zu
    Journal: Frontiers in Medicine (Lausanne)
    Published 6 months ago

    TITLE: First-Line Combination Therapies Superior in Unresectable Hepatocellular Carcinoma: A Parametric Survival Analysis of Phase III Trials SUMMARY: This systematic review and pooled analysis evalu...

    TITLE: 2025 HKUA-HKSUO Consensus Guidelines: Management of Locally Advanced and Metastatic Renal Cell Carcinoma SUMMARY: The Hong Kong Urological Association (HKUA) and the Hong Kong Society of Uro-O...

    FDA Advisors Split on Regimens for Breast, Prostate Cancers

    Author: Sharon Worcester
    Journal: Medscape
    Published 6 months ago

    TITLE: FDA Advisory Committee Split on New Regimens for Breast and Prostate Cancers SUMMARY: The FDA's Oncologic Drugs Advisory Committee (ODAC) recently evaluated new therapeutic regimens for breast...

    Hepatocellular Carcinoma in the Immunotherapy Era: A SEER-Based Era Comparison Across the U.S. FDA Transition

    Author: Lv et al
    Journal: European Journal of Surgical Oncology
    Published 6 months ago

    TITLE: Hepatocellular Carcinoma Outcomes in the Immunotherapy Era: A SEER-Based Analysis of FDA Transition Impact SUMMARY: This study, published in the European Journal of Surgical Oncology, utilizes...

    TITLE: Priority vs. Nonpriority Review: Cancer Drug Approval Times and Therapeutic Value in the US, EU, and Switzerland (2010-2024) SUMMARY: Published in JCO Oncology Practice, this study investigate...

    TITLE: Impact of Diabetes Mellitus on Treatment Efficacy in Advanced Pancreatic Cancer: The PANCAKE Study SUMMARY: The PANCAKE study is a multicenter, observational research effort conducted in Italy...

    TITLE: Post-Transplant Maintenance Therapy Patterns in Older Adults with AML: A Medicare Cohort Study SUMMARY: A study published in the Journal of Geriatric Oncology examines the real-world utilizati...

    Survey reveals ‘roadmap’ to improved pediatric oncology discourse

    Author: Josh Friedman
    Journal: Healio
    Published 7 months ago

    TITLE: Optimizing Prognostic Communication in Pediatric Oncology: A Multi-Stakeholder Survey Analysis SUMMARY: Prognostic communication in pediatric oncology is frequently complicated by the divergen...

    TITLE: Fall Prevention in Older Patients with Cancer: EuGMS Gero-Oncology Call for Action SUMMARY: The European Geriatric Medicine Society (EuGMS) Special Interest Group on Gero-Oncology has issued a...

    TITLE: International Multisociety Standards for Liver Tumor Thermal Ablation: A Delphi Consensus Policy Review SUMMARY: Thermal ablation serves as a safer, minimally invasive, and cost-effective alte...

    TITLE: Noncompete Agreements in Gynecologic Oncology: SGO Member Knowledge and Perspectives Survey SUMMARY: This study, published in Gynecologic Oncology, investigates the knowledge and perspectives ...

    Celcuity’s gedatolisib beats Novartis’ Piqray in phase 3 breast cancer study

    Author: Nick Paul Taylor
    Journal: Fierce Biotech
    Published 7 months ago

    TITLE: Gedatolisib Outperforms Alpelisib in Phase 3 Breast Cancer Trial SUMMARY: Celcuity has announced that its investigational pan-PI3K/mTOR inhibitor, gedatolisib, successfully met the primary end...

    FDA hands Pfizer, Arvinas’ Veppanu early approval for breast cancer subtype

    Author: Zoey Becker
    Journal: Fierce Pharma
    Published 7 months ago

    TITLE: Veppanu (Pfizer, Arvinas) Receives Early FDA Approval for Breast Cancer Subtype SUMMARY: Veppanu, developed by Pfizer and Arvinas, has received early FDA approval from the FDA for a specific b...

    Guidelines Can Be Lifesaving: The Vermont Model of Thromboprophylaxis Implementation

    Author: Dana Angelini, MD & Alok A. Khorana, MD, FASCO
    Journal: JCO Oncology Practice
    Published 7 months ago

    TITLE: Vermont Model for Thromboprophylaxis Implementation: Lifesaving Guidelines in Oncology Practice SUMMARY: The article, published in JCO Oncology Practice, examines the Vermont Model for impleme...

    STAT+: FDA launches effort to speed up clinical trials, using AI

    Author: Lizzy Lawrence
    Journal: STAT
    Published 7 months ago

    TITLE: FDA Initiatives: Real-Time Data Review and AI Integration to Accelerate Clinical Trials SUMMARY: The Food and Drug Administration (FDA) has announced new initiatives aimed at enhancing the eff...

    NCCN publishes new patient guide for prostate cancer screening

    Author: National Comprehensive Cancer Network
    Journal: News Medical
    Published 7 months ago

    TITLE: NCCN Publishes New Patient Guide Detailing Prostate Cancer Screening Evidence and Recommendations SUMMARY: The National Comprehensive Cancer Network® (NCCN®), an alliance of leading cancer cen...

    TITLE: Circulating Tumor DNA for Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel vs. Autologous Stem Cell Transplantation SUMMARY: This article, published in the Journal of Clinic...

    EHR Burden in Oncology Is Taking a Toll. Is There a Fix?

    Author: Christina Szalinski
    Journal: Medscape
    Published 7 months ago

    TITLE: EHR Burden in Oncology: Impact on Patient Relationships and Documentation Challenges SUMMARY: Oncologists are experiencing a growing documentation burden and challenges with overflowing patien...

    Merck KGaA, Remepy team up on software-enhanced hybrid drugs for rare tumors

    Author: Natalie Missakian
    Journal: Fierce Biotech
    Published 7 months ago

    TITLE: Merck KGaA and Remepy Partner to Develop AI-Driven Hybrid Drugs for Rare Tumors SUMMARY: German drugmaker Merck KGaA is collaborating with Israeli biotech Remepy to develop hybrid drugs. These...

    Eli Lilly to Acquire Ajax Therapeutics in USD 2.3 Billion Cancer Drug Push

    Author: Sheeba Farhat
    Journal: Medical Dialogues
    Published 7 months ago

    TITLE: Eli Lilly Acquires Ajax Therapeutics for Novel JAK2 Inhibitor AJ1-11095 in Myelofibrosis SUMMARY: Eli Lilly is set to acquire Ajax Therapeutics, expanding its oncology pipeline with AJ1-11095,...

    Advances in anal cancer treatment: current standards, the role of immunotherapy and emerging strategies

    Author: Ntellas et al
    Journal: ESMO Gastrointestinal Oncology
    Published 7 months ago

    TITLE: Anal Cancer Treatment: Current Standards, Immunotherapy, and Emerging Strategies SUMMARY: This article discusses current standards, the role of immunotherapy, and emerging strategies in the tr...

    FDA lambasts Incyte over ‘misleading’ Niktimvo claims

    Author: Ben Adams
    Journal: Fierce Pharma
    Published 7 months ago

    TITLE: FDA Raises Concerns Over Incyte's Niktimvo Promotional Claims SUMMARY: The U.S. Food and Drug Administration (FDA) has expressed concerns regarding promotional claims made by Incyte for its ch...

    Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4

    Author: Armstrong et al
    Journal: Journal of Clinical Oncology
    Published 7 months ago

    TITLE: Recommendations for Prostate Cancer Clinical Trial Design and Objectives SUMMARY: This article, published in the Journal of Clinical Oncology (Ahead of Print), outlines recommendations from th...

    UK real-world evidence on pembrolizumab and neoadjuvant chemotherapy for early-stage triple-negative breast cancer

    Author: Early-Stage Immunotherapy Study Group
    Journal: ESMO Real World Data and Digital Oncology
    Published 7 months ago

    TITLE: UK Real-World Evidence on Pembrolizumab and Neoadjuvant Chemotherapy for Early-Stage Triple-Negative Breast Cancer SUMMARY: This article presents UK real-world evidence regarding the use of pe...

    Treatment Delays for Metastatic Breast Cancer Vary by Race

    Author: Katie Lennon
    Journal: Medscape
    Published 7 months ago

    TITLE: Racial Disparities in Metastatic Breast Cancer Treatment Delays SUMMARY: A retrospective cross-sectional analysis investigated racial differences in treatment delays and presentation among pat...

    Alternative medicine linked with worse survival in breast cancer

    Author: Josh Friedman
    Journal: Healio
    Published 7 months ago

    TITLE: Complementary and Alternative Medicine Use Associated with Worse Breast Cancer Survival SUMMARY: An evaluation of over 2 million women with breast cancer revealed that those treated with compl...

    TITLE: Large Language Models vs. Human Physicians: Decision-Making Performance in Challenging Lung Cancer Cases SUMMARY: This real-world case-based study investigated the decision-making performance ...

    EMA Recommends Generic in Advanced/Metastatic Breast Cancer

    Author: Sophie Cousins
    Journal: Medscape
    Published 7 months ago

    TITLE: EMA Recommends Generic Palbociclib for HR+/HER2- Advanced/Metastatic Breast Cancer SUMMARY: The European Medicines Agency (EMA) has issued a recommendation for a generic version of palbociclib....

    CAR T-cell therapy may prevent progression of smoldering myeloma

    Author: Mark Leiser
    Journal: Healio
    Published 7 months ago

    TITLE: CAR T-Cell Therapy Ciltacabtagene Autoleucel Shows Sustained Benefit in High-Risk Smoldering Myeloma, Preventing Progression SUMMARY: A phase 2 trial has demonstrated that chimeric antigen rece...

    ONS/ASCO Guideline on the Management of Antineoplastic Extravasation

    Author: Thomas et al
    Journal: JCO Oncology Practice
    Published 7 months ago

    TITLE: ONS/ASCO Guideline: Evidence-Based Management of Antineoplastic Extravasation for Oncology Professionals SUMMARY: The Oncology Nursing Society (ONS) and the American Society of Clinical Oncolog...

    An electronic geriatric assessment platform (eGAP) for older patients with cancer

    Author: Blumberg et al
    Journal: Journal of Geriatric Oncology
    Published 7 months ago

    TITLE: Electronic Geriatric Assessment Platform (eGAP) for Older Patients with Cancer: Optimizing Care SUMMARY: This article introduces an electronic geriatric assessment platform (eGAP) designed for ...

    NICE Recommends Combination Treatment for Advanced NSCLC

    Author: Rob Hicks
    Journal: Medscape
    Published 7 months ago

    TITLE: NICE Recommends First-Line Oral Dabrafenib/Trametinib for BRAF V600E-Mutated Advanced NSCLC SUMMARY: The National Institute for Health and Care Excellence (NICE) has published final draft guida...

    Measurable Residual Disease Predicts Real-World AML Relapse

    Author: Nancy A. Melville
    Journal: Medscape
    Published 7 months ago

    TITLE: Measurable Residual Disease Thresholds Predict Relapse in Real-World NPM1-Mutated AML, Informing Treatment Decisions SUMMARY: A recent real-world study has reinforced the prognostic significanc...

    TITLE: NEO-RT Organ Preservation Trial for Early Rectal Cancer: CCTG CO.32 Phase III Randomized Trial of Neoadjuvant Chemotherapy, Excision and Observation Versus Chemoradiotherapy SUMMARY: This artic...

    TITLE: CAPItello-281 Phase III: Investigating Capivasertib + Abiraterone in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer SUMMARY: This entry pertains to the CAPItello-281 Phase III stud...

    STAT+: Replimune skin cancer drug that became FDA flashpoint is rejected again

    Author: Jason Mast
    Journal: STAT
    Published 7 months ago

    TITLE: FDA Rejects Replimune's Experimental Oncolytic Virus for Advanced Melanoma, Again SUMMARY: The U.S. Food and Drug Administration (FDA) has issued a second rejection for Replimune Group's invest...

    TITLE: Bridging Gaps in Lymphoma Management: Expert Consensus on MCL, CLL, and DLBCL Strategies SUMMARY: The Bridging the Gaps (BTG) in Leukemia, Lymphoma and Multiple Myeloma Consensus Conference 202...

    TITLE: Optimizing Pembrolizumab Dosing for Triple-Negative Breast Cancer: Implications for Equitable Care SUMMARY: This analysis is based solely on the provided article title, as the full content was ...

    Living Guidelines for Tumor-Agnostic Therapies: A Pathway to Next-Generation Cancer Treatment

    Author: Subbiah et al
    Journal: JCO Precision Oncology
    Published 7 months ago

    TITLE: Clinical Guidelines for Tumor-Agnostic Therapies: Advancing Next-Generation Cancer Treatment SUMMARY: The provided article, published in JCO Precision Oncology, Volume 10, Issue 4, introduces t...

    HosTIL territory: mapping the landscape of toxicity in TIL therapy

    Author: Woodford et al
    Journal: Journal for ImmunoTherapy of Cancer
    Published 7 months ago

    TITLE: Navigating Toxicity in Tumor-Infiltrating Lymphocyte (TIL) Therapy for Advanced Melanoma SUMMARY: Tumor-infiltrating lymphocyte (TIL) therapy has recently received US FDA and Health Canada appr...

    Enhancing engagement in biobanking research among Black women with endometrial cancer

    Author: Salehipour et al
    Journal: Gynecologic Oncology
    Published 7 months ago

    TITLE: Enhancing Biobanking Engagement in Black Women with Endometrial Cancer: Strategies and Impact SUMMARY: The provided information consists solely of a title, publication details, and author list ...

    Geriatric oncology in 2040: Exploring potential realities and challenges. A diverse perspective

    Author: Gardner et al
    Journal: Journal of Geriatric Oncology
    Published 7 months ago

    TITLE: Geriatric Oncology in 2040: Anticipating Future Realities and Clinical Challenges SUMMARY: This analysis is based solely on the provided title and author list, as the full article content was n...

    How Much Is Enough? Ultra-Low Doses of Immunotherapy to Improve Access and Affordability

    Author: M. Raheel Khan, MD and Patrick M. Forde, MD
    Journal: Journal of Clinical Oncology
    Published 7 months ago

    TITLE: Ultra-Low Dose Immunotherapy: Exploring Efficacy, Access, and Affordability in Oncology SUMMARY: This article from the Journal of Clinical Oncology, "Ahead of Print," explores the concept of us...

    TITLE: VIKTORIA-1 Trial Investigates Gedatolisib Combinations in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer SUMMARY: The VIKTORIA-1 trial is an "Ahead of Print" publication from the Journal of ...

    TITLE: Darolutamide Delays Pain Progression and Preserves Quality of Life in mHSPC: ARANOTE Phase 3 Secondary Analysis SUMMARY: Secondary and exploratory analyses of the multicenter, randomized, place...

    TITLE: Prospective Evaluation of Cardiovascular Effects of BRAF and MEK Inhibitors in Melanoma Targeted Therapy SUMMARY: BRAF and MEK inhibitors are cornerstone targeted therapies for patients with BR...

    TITLE: Brentuximab Vedotin and Dose-Attenuated Chemoimmunotherapy in Elderly DLBCL: Analyzing Outcomes by Frailty SUMMARY: This article investigates the efficacy and safety of a treatment regimen comb...

    TITLE: Phase III TROPION-Breast02 Trial Investigating Datopotamab Deruxtecan in Untreated, Advanced Triple-Negative Breast Cancer SUMMARY: The TROPION-Breast02 trial is an international, open-label, r...

    Oncology Drug Development: Challenges of Increasingly Available Therapies

    Author: Sundeep Agrawal, MD and Richard Padzur, MD
    Journal: Journal of Clinical Oncology
    Published 8 months ago

    TITLE: Oncology Drug Development: Navigating Challenges of Expanding Therapeutic Options SUMMARY: The provided article content is insufficient to generate a comprehensive summary that meets the specif...

    STAT+: FDA backs proposals to entice pharma companies to test, make drugs domestically

    Author: John Wilkerson and Lizzy Lawrence
    Journal: STAT
    Published 8 months ago

    TITLE: FDA Proposes Policies to Boost Domestic Drug Development and Manufacturing SUMMARY: The Food and Drug Administration (FDA) has outlined new policy proposals aimed at incentivizing the domestic ...

    Is Progression-Free Survival 2 Ready for Prime Time in US Food and Drug Administration Regulatory Decision Making?

    Author: Fiero et al
    Journal: Journal of Clinical Oncology
    Published 8 months ago

    TITLE: Progression-Free Survival 2 (PFS2) as an FDA Regulatory Endpoint in Oncology: A Critical Evaluation** SUMMARY: This article from the Journal of Clinical Oncology critically evaluates the readin...

    TITLE: HER2 Gene Alterations as a Biomarker in Metastatic Colorectal Cancer Patients Treated with FOLFIRI and Cetuximab: The CAPRI-2 GOIM Study SUMMARY: The CAPRI-2 GOIM study investigates the potenti...

    TITLE: Adjuvant Abemaciclib in HR+/HER2- Breast Cancer with Locoregional Recurrence: JCOG2313 AURA Phase III Trial Protocol SUMMARY: This entry describes the protocol for JCOG2313, also known as the A...

    FDA extends review of Orca Bio’s novel cell therapy for blood cancers

    Author: Angus Liu
    Journal: Fierce Biotech
    Published 8 months ago

    TITLE: FDA Extends PDUFA Date for Orca-T Cell Therapy in Blood Cancers SUMMARY: The U.S. Food and Drug Administration (FDA) has extended its target decision date for Orca Bio's investigational cell th...

    Still reeling from FDA refusal, IO Biotech surrenders to bankruptcy

    Author: Darren Incorvaia
    Journal: Fierce Biotech
    Published 8 months ago

    TITLE: Biotechnology Firm IO Biotech Declares Bankruptcy Following FDA Refusal of Investigational Therapy SUMMARY: IO Biotech, a biotechnology company, has announced its cessation of operations and de...

    TITLE: Metabolic Subtyping in Nasopharyngeal Carcinoma: A Novel Biomarker for Optimizing Immunotherapy in Phase III CONTINUUM and DIPPER Trials SUMMARY: Researchers have developed and validated a meta...

    TITLE: Long-Term Efficacy of First-Line Nivolumab plus Ipilimumab in Advanced Renal Cell Carcinoma: Final CheckMate 214 Analysis SUMMARY: The final analysis of the landmark Phase III CheckMate 214 tri...

    TITLE: Oral Zegfrovy Achieves Positive Phase 3 Results in Non-Small Cell Lung Cancer Subtype, Poised to Compete with Rybrevant SUMMARY: Dizal has announced positive Phase 3 clinical trial results for ...

    Regulatory tracker: BMS' Opdivo nabs triplet of FDA lymphoma endorsements

    Author: Liu et al
    Journal: Fierce Pharma
    Published 8 months ago

    TITLE: FDA Grants Multiple Designations to Nivolumab (Opdivo) for Lymphoma Indications SUMMARY: The FDA has granted a series of regulatory endorsements to Bristol Myers Squibb’s nivolumab (Opdivo), a ...

    TITLE: Phase III OPTIMAL Trial: Oral Paclitaxel (DHP107) Demonstrates Non-Inferiority to Weekly IV Paclitaxel in HER2-Negative Metastatic Breast Cancer SUMMARY: The OPTIMAL study, a multinational Phas...

    TITLE: First-Line Pembrolizumab Plus Lenvatinib for R/M Head and Neck Squamous Cell Carcinoma: Results from the Phase III LEAP-010 Study SUMMARY: The Phase III LEAP-010 study evaluated the efficacy an...

    TITLE: Impact of Accelerated Drug Marketing Registration Procedures on NSCLC Targeted Therapy Efficacy in China SUMMARY: A retrospective study evaluated the clinical efficacy and regulatory landscape ...

    TITLE: Management and Characterization of Grade 3-4 Immune Checkpoint Inhibitor-Induced Hepatitis: A Prospective Study SUMMARY: This prospective study (NCT04810156) investigated the clinical phenotype...

    FDA approves first treatment for smoldering multiple myeloma

    Author: Leah Lawrence
    Journal: Cancer
    Published 9 months ago

    TITLE: FDA Approves Daratumumab-Hyaluronidase as First Treatment for High-Risk Smoldering Multiple Myeloma SUMMARY: The U.S. Food and Drug Administration (FDA) has granted approval for daratumumab and...

    Biomarkers and Cardiotoxicity in Breast Cancer: A Step Forward and More Studies Needed

    Author: Alan H. Baik MD
    Journal: JACC: CardioOncology
    Published 9 months ago

    TITLE: Clinical Utility of Biomarkers for Monitoring Cardiotoxicity in Breast Cancer Patients SUMMARY: This analysis from *JACC: CardioOncology* evaluates the evolving role of cardiac biomarkers, spec...

    Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer

    Author: DESTINY-Breast05 Trial Investigators
    Journal: NEJM
    Published 9 months ago

    TITLE: Trastuzumab Deruxtecan vs. Trastuzumab Emtansine for Residual HER2-Positive Early Breast Cancer: DESTINY-Breast05 Trial Results SUMMARY: The phase 3 DESTINY-Breast05 randomized clinical trial e...

    TITLE: Axitinib Combined With Octreotide LAR in Advanced Extrapancreatic Neuroendocrine Tumors: Results From the Phase III AXINET Trial SUMMARY: The AXINET (GETNE 1107) study, a multicenter, randomize...

    TITLE: Nutritional Risk Screening as a Prognostic Indicator in Metastatic Esophagogastric Adenocarcinoma: AIO-MATEO Trial Analysis SUMMARY: This secondary analysis of the prospective, randomized AIO-M...

    FDA freezes enrollment in MacroGenics cancer trial after patient death

    Author: Darren Incorvaia
    Journal: Fierce Biotech
    Published 9 months ago

    TITLE: FDA Places Partial Clinical Hold on MacroGenics Phase 2 Lorigerlimab Trial Following Patient Fatality SUMMARY: The U.S. Food and Drug Administration (FDA) has implemented a partial clinical hol...

    FDA Grants Full Approval to Encorafenib in Metastatic CRC

    Author: Megan Brooks
    Journal: Medscape
    Published 9 months ago

    TITLE: FDA Grants Full Approval to Encorafenib-Cetuximab Combination for BRAF V600E-Mutant Metastatic Colorectal Cancer SUMMARY: The U.S. Food and Drug Administration (FDA) has transitioned the accele...

    Acalabrutinib-venetoclax combination gets FDA nod for CLL

    Author: Matthew Shinkle
    Journal: Healio
    Published 9 months ago

    TITLE: FDA Approves Acalabrutinib-Venetoclax for First-Line CLL/SLL SUMMARY: The FDA has granted approval for the first all-oral, fixed-duration, first-line regimen for chronic lymphocytic leukemia (C...

    TITLE: Cardiovascular Events and Cardiac Dysfunction in Acute Leukemia: A Prospective Analysis SUMMARY: This prospective study investigated the incidence of major adverse cardiovascular events (MACE) ...

    TITLE: Geriatric Co-Management Improves Independence and Reduces Toxicity in Vulnerable Older Cancer Patients SUMMARY: A randomized clinical trial investigated the impact of geriatric co-management on...

    TITLE: Trends in Conflicts of Interest in *JCO* Clinical Trials: A Large Language Model-Assisted Analysis SUMMARY: A longitudinal study utilizing a large language model (LLM) analyzed financial confli...

    An overview of clinical trials in anal cancer 1999-2024

    Author: Verschoor et al
    Journal: ESMO Gastrointestinal Oncology
    Published 9 months ago

    TITLE: Anal Cancer Clinical Trials: A 25-Year Overview (1999-2024) SUMMARY: This overview summarizes clinical trial activity in anal cancer from 1999 to 2024, providing a comprehensive landscape of re...

    Agilent companion diagnostic lands FDA nod alongside Keytruda's latest cancer approval

    Author: Ben Adams
    Journal: Fierce Biotech
    Published 9 months ago

    TITLE: Agilent's Companion Diagnostic for Ovarian Cancer Gains FDA Approval Alongside Keytruda SUMMARY: The FDA has approved Agilent Technologies' companion diagnostic, the PD-L1 IHC 22C3 pharmDx, to ...

    TITLE: Patient-Reported Quality of Life with Moderately Hypofractionated Radiotherapy for Intermediate-Risk Prostate Cancer SUMMARY: This Phase 3 randomized clinical trial, PROFIT, investigated patien...

    TITLE: Neoadjuvant Carboplatin Integration in HER2-Positive Breast Cancer: Noninferiority of Taxane/Trastuzumab/Pertuzumab Regimen SUMMARY: The neoCARHP trial, a randomized noninferiority Phase III st...

    Immunotherapy Regimen Approved for Recurrent Ovarian Cancer

    Author: Mike Bassett
    Journal: MedPage Today
    Published 9 months ago

    TITLE: FDA Approves Pembrolizumab with Paclitaxel for PD-L1 Positive Recurrent Ovarian Cancer SUMMARY: The U.S. Food and Drug Administration (FDA) has granted accelerated approval for pembrolizumab (K...

    TITLE: Pharmacist Intervention Reduces ADRs and Medication Errors in Hematology-Oncology: A RCT SUMMARY: This randomized controlled trial investigated the impact of a designated pharmacist on adverse ...

    TITLE: Toripalimab Plus Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma: Final Overall Survival and Biomarker Analysis from JUPITER-06 SUMMARY: The JUPITER-06 trial, a randomized phase 3 s...

    TITLE: Circulating Vascular Biomarkers Predict Cardiotoxicity in HER2+ Breast Cancer Therapy SUMMARY: A study published in JACC: CardioOncology investigated the utility of pretreatment circulating vas...

    TITLE: Oncological Safety of Autologous Fat Transfer in Total Breast Reconstruction: BREAST-I and BREAST-II Trials SUMMARY: The multicenter BREAST-I and BREAST-II trials provide crucial evidence regar...

    TITLE: Circulating Tumor DNA (ctDNA) Predicts Recurrence and Survival in Stage III Colon Cancer Post-FOLFOX Adjuvant Chemotherapy SUMMARY: A prospective analysis from the Alliance N0147 phase III tria...

    TITLE: Nelfinavir Mesylate with Chemoradiation and Brachytherapy for Stage III Cervical Cancer: Phase III Trial Results SUMMARY: This Phase III clinical trial investigated the efficacy and safety of a...

    Reduced Exercise Capacity in Breast Cancer Compared to HFpEF: Mechanistic Insights From Invasive Exercise Testing

    Author: Landsteiner et al
    Journal: JACC: CardioOncology
    Published 10 months ago

    TITLE: Invasive Exercise Testing Reveals Reduced Exercise Capacity in Breast Cancer Patients Compared to HFpEF SUMMARY: This study, published in JACC: CardioOncology, utilized invasive cardiopulmonary...

    Spreading drug costs over the year may ease financial burden for Medicare cancer patients

    Author: University of California - San Diego
    Journal: Medical Xpress
    Published 10 months ago

    TITLE: Medicare Prescription Payment Plan: Easing Financial Burden for Cancer Patients SUMMARY: The Medicare Prescription Payment Plan (M3P), an opt-in policy effective in 2025 under the Inflation Red...

    Single-drug Exelixis aims to be top 5 solid tumor company in the US: CEO

    Author: Angus Liu
    Journal: Fierce Pharma
    Published 10 months ago

    TITLE: Exelixis Eyes Top-Tier Solid Tumor Market Position with Cabozantinib and Expanding Pipeline SUMMARY: Exelixis, currently known for its single marketed drug, Cabometyx (cabozantinib), is strateg...

    TITLE: Upfront mFOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: TRIPLETE Study Final Results SUMMARY: The phase III TRIPLETE study demonstrates that upfront modified FO...

    TITLE: Anbenitamab for Previously Treated HER2-Positive Gastric Cancer: Interim Analysis of Phase III KC-WISE Trial SUMMARY: A pre-specified interim analysis of the randomized, phase III KC-WISE trial...

    FDA loosens AI oversight: What clinicians need to know about the 2026 guidance

    Author: Arthur Lazarus, MD, MBA
    Journal: KevinMD.com
    Published 10 months ago

    TITLE: FDA Revises AI Oversight for Clinical Decision Support: Implications for Clinicians SUMMARY: The FDA announced revised guidance in 2026, significantly loosening oversight for certain AI-enabled...

    TITLE: HER2CLIMB-05: Tucatinib, Trastuzumab, and Pertuzumab as First-Line Maintenance for HER2+ Metastatic Breast Cancer SUMMARY: The HER2CLIMB-05 study is a Phase III, randomized, double-blind, place...

    TITLE: Deep PSA Response to Darolutamide + ADT Linked to Improved Outcomes in mHSPC: ARANOTE Trial SUMMARY: A post-hoc analysis of the Phase 3 ARANOTE trial, published in European Urology Oncology, in...

    TITLE: CAPItello-290: Capivasertib Plus Paclitaxel in First-Line Metastatic Triple-Negative Breast Cancer SUMMARY: The CAPItello-290 trial, a global, randomized Phase III study, investigated the effic...

    TITLE: FDA Regulatory Harmonization Opportunities: Sotorasib and Panitumumab in Colorectal Cancer SUMMARY: This analysis, published in the Journal of Clinical Oncology, highlights opportunities for ha...

    Neutropenic diet best during blood cancer treatment

    Author: Mark Leiser
    Journal: Healio
    Published 10 months ago

    TITLE: Neutropenic Diet Reduces Infection Risk in Blood Cancer Patients Undergoing Intensive Treatment SUMMARY: A randomized phase 3 noninferiority trial indicates that a neutropenic diet significantl...

    TITLE: Unmet Care Needs in Older Adults with Cancer: Insights from National Health and Aging Trends Study SUMMARY: A retrospective analysis of the 2015-2019 National Health and Aging Trends Study (NHA...

    TITLE: Aumolertinib Adjuvant Therapy for Resected EGFR-Mutated NSCLC: Phase 3 ARTS Trial Results SUMMARY: The phase 3 ARTS trial demonstrated significant clinical benefits of aumolertinib as adjuvant ...